New cocktail of four drugs takes on advanced colorectal cancer
NCT ID NCT07395063
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a combination of four drugs—irinotecan liposome, capecitabine, bevacizumab, and camrelizumab—as a second or later treatment for people with metastatic colorectal cancer. The study will enroll 68 participants and measure how long the disease stays under control. The goal is to see if this mix can shrink tumors and delay progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- irinotecan liposome, capecitabine, bevacizumab, and camrelizumab
- What this could lead to
- If this works, it could offer a new treatment option for people with metastatic colorectal cancer who have already tried one line of therapy.
- What could go wrong
- This is a small, early-phase trial with no control group, so results may not be definitive. The combination of drugs may cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (CRC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can mindfulness together ease the burden of advanced cancer?
- Can a Two-Pronged attack shrink Hard-to-Treat colorectal tumors?
- Blood test may reveal hidden cancer spread without scans
- Mouth bacteria may predict colon cancer drug resistance
- New cocktail attack on stubborn colon cancer
- New chemo cocktail aims to slow advanced colon cancer